The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
· Financial Post
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met Read More
Visit betsport.cv for more information.